Teva and Regeneron team up for $2.6 billion pain treatment development
pharmafile | September 21, 2016 | News story | Research and Development, Sales and Marketing | Regeneron, Teva, fasinumab, osteoarthritis
Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve growth factor (NGF) antibody fasinumab.
Fasinumab is in late-stage development for the treatment of osteoarthritis pain and is also undergoing Phase II testing for use against chronic low back pain. The product showed a “significant” margin of efficacy in treating pain versus placebo in a recent Phase II/III study examining adults with moderate-to-severe osteoarthritis of the hip or knee.
“Fasinumab has shown proof of concept in early clinical trials, and represents an exciting novel target for pain relief,” remarked Michael Hayden, president of global R&D at Teva. “It has the potential to provide a treatment option without the concerns of abuse, addiction and misuse of opioids.”
Teva will make an upfront payment of $250 million as stipulated in the deal and is also eligible to receive up to $460 million in milestone payments and contingent payments of up to $1.9 billion based on annual net sales. Both companies will equally share the global commercial value of the drug and its $1 billion R&D costs.
The deal also calls for Regeneron to head up global development and US commercialisation for fasinumab, with both companies devoting staff to US marketing efforts. Teva will be responsible for marketing in regions outside of the US that are not covered by Regeneron’s collaboration with Mitsubishi Tanabe Pharma.
Matt Fellows
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …
